Ovarian cancer screening: are we making any progress?
Given the burden of suffering associated with the development of ovarian cancer and the clear survival gradient related to the stage of disease at diagnosis, there is much enthusiasm for the development of effective screening strategies aimed at early detection. To date, no evidence exists to justify mass population screening; however, emphasis on subpopulation screening, identification of novel serologic markers, and multimodality screening designs have provided hope that these refinements may eventually translate into a reduction in ovarian cancer mortality.
Paley
P J
PJ
University of Washington School of Medicine, Seattle, Washington 98195-6460, USA. paley@u.washington.edu
D015415:Biomarkers; D005260:Female; D006801:Humans; D015994:Incidence; D008017:Life Expectancy; D008403:Mass Screening; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000401:mortality; D011379:Prognosis; D012307:Risk Factors; D012698:Serologic Tests
D015415:Biomarkers